PYPD Similar Chart Price Prediction
The price of PYPD is predicted to go up -3.64%, based on the high correlation periods with LTBR. The similarity of these two price pattern on the periods is 91.14%.
PYPD
LTBR
Down: -3.64%Similarity: 91.14%
PYPD Revenue Forecast
PYPD EPS Forecast
PYPD FAQs
What is bull’s view on PYPD?
What is bear's view on PYPD?
What is PYPD eps forecast for next quarter？
PYPD Analyst's Forecast
Chase Knickerbocker
Craig-Hallum
Strong Buy
2024-11-04
Price Target
$10
Upside
+200.3%
As previously reported, Craig-Hallum initiated coverage of PolyPid with a Buy rating and $10 price target. The firm believes investors have completely forgotten about PolyPid, which has quietly pivoted following a late 2022 Phase 3 failure for its lead asset, D-PLEX100. PolyPid is nearing a pivotal Phase 3 data set that Craig-Hallum thinks will support approval for prevention of surgical site infection in colorectal/abdominal surgeries. Further, the firm believes this is a $1.5B market in high-risk patients undergoing open procedures, and that the stock is currently pricing in a 15% chance of success in the ongoing Phase 3, SHIELD 2 trial. At the very least, Craig-Hallum thinks probability of success is no worse than a typical Phase 3 trial, and models 50% POS.
